Update on Gastrointestinal Stromal Tumors for Radiologists.
- Author:
Sree Harsha TIRUMANI
1
;
Akshay D BAHETI
;
Harika TIRUMANI
;
Ailbhe O'NEILL
;
Jyothi P JAGANNATHAN
Author Information
- Publication Type:Review
- Keywords: Gastrointestinal stromal tumor; Imatinib; Risk stratification; Choi criteria
- MeSH: Exons; Gastrointestinal Stromal Tumors*; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Recurrence; Succinate Dehydrogenase
- From:Korean Journal of Radiology 2017;18(1):84-93
- CountryRepublic of Korea
- Language:English
- Abstract: The management of gastrointestinal stromal tumors (GISTs) has evolved significantly in the last two decades due to better understanding of their biologic behavior as well as development of molecular targeted therapies. GISTs with exon 11 mutation respond to imatinib whereas GISTs with exon 9 or succinate dehydrogenase subunit mutations do not. Risk stratification models have enabled stratifying GISTs according to risk of recurrence and choosing patients who may benefit from adjuvant therapy. Assessing response to targeted therapies in GIST using conventional response criteria has several potential pitfalls leading to search for alternate response criteria based on changes in tumor attenuation, volume, metabolic and functional parameters. Surveillance of patients with GIST in the adjuvant setting is important for timely detection of recurrences.
